JP2021530217A5 - - Google Patents
Info
- Publication number
- JP2021530217A5 JP2021530217A5 JP2021500519A JP2021500519A JP2021530217A5 JP 2021530217 A5 JP2021530217 A5 JP 2021530217A5 JP 2021500519 A JP2021500519 A JP 2021500519A JP 2021500519 A JP2021500519 A JP 2021500519A JP 2021530217 A5 JP2021530217 A5 JP 2021530217A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- isolated nucleic
- polypeptide
- cell
- acid according
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024022330A JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696075P | 2018-07-10 | 2018-07-10 | |
| US62/696,075 | 2018-07-10 | ||
| PCT/US2019/041213 WO2020014366A1 (en) | 2018-07-10 | 2019-07-10 | Ror-1 specific chimeric antigen receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022330A Division JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530217A JP2021530217A (ja) | 2021-11-11 |
| JPWO2020014366A5 JPWO2020014366A5 (https=) | 2022-07-12 |
| JP2021530217A5 true JP2021530217A5 (https=) | 2022-07-12 |
Family
ID=69141807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500519A Pending JP2021530217A (ja) | 2018-07-10 | 2019-07-10 | Ｒｏｒ−１特異的キメラ抗原受容体およびその使用 |
| JP2024022330A Pending JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022330A Pending JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12275772B2 (https=) |
| EP (1) | EP3820484A4 (https=) |
| JP (2) | JP2021530217A (https=) |
| KR (1) | KR20210043562A (https=) |
| CN (1) | CN112714769A (https=) |
| AU (1) | AU2019301147B2 (https=) |
| CA (1) | CA3105816A1 (https=) |
| IL (1) | IL280029A (https=) |
| SG (1) | SG11202100205UA (https=) |
| WO (1) | WO2020014366A1 (https=) |
| ZA (1) | ZA202100391B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3697438A4 (en) * | 2017-10-18 | 2021-08-18 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS WITH SPACERS |
| EP3820484A4 (en) | 2018-07-10 | 2022-05-04 | Precigen, Inc. | ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF |
| US20210388317A1 (en) * | 2018-10-26 | 2021-12-16 | Shinshu University | High-efficiency method for producing genetically modified cells |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| IL296511A (en) | 2020-03-20 | 2022-11-01 | Lyell Immunopharma Inc | Novel recombinant cell surface markers |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN113584083A (zh) * | 2020-04-30 | 2021-11-02 | 深圳市深研生物科技有限公司 | 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法 |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| WO2022097068A1 (en) | 2020-11-05 | 2022-05-12 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| MX2023008115A (es) * | 2021-01-11 | 2023-09-11 | Precigen Inc | Terapia con receptores quiméricos. |
| AU2022211682A1 (en) | 2021-01-22 | 2023-08-03 | Mendus B.V. | Methods of tumor vaccination |
| US20240415883A1 (en) * | 2021-02-01 | 2024-12-19 | The Regents Of The University Of California | Treatment of neuroendocrine cancers |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| JP2024508597A (ja) * | 2021-03-09 | 2024-02-28 | 四川科倫博泰生物医薬股▲フン▼有限公司 | Ｒｏｒ１結合タンパク質及びその用途 |
| MX2024002172A (es) * | 2021-08-18 | 2024-07-10 | Univ Pennsylvania | Composiciones y métodos para receptores de antígenos quiméricos específicos para receptores de células b. |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| IL316226A (en) * | 2022-05-24 | 2024-12-01 | Caribou Biosciences Inc | Anti-ror1 antibody and ror1-targeting engineered cells |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN118206620A (zh) * | 2022-12-09 | 2024-06-18 | 上海细胞治疗集团股份有限公司 | 一种多肽标签及其应用 |
| CN116284246B (zh) * | 2022-12-12 | 2025-11-14 | 江苏三联生物工程股份有限公司 | 信号肽、核酸片段、重组表达载体、宿主细胞及其应用 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025194140A1 (en) * | 2024-03-15 | 2025-09-18 | Port Therapeutics, Inc. | Thermally controlled gene expression and uses thereof |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| AU734051B2 (en) | 1996-04-05 | 2001-05-31 | Salk Institute For Biological Studies, The | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| AU738494B2 (en) | 1997-07-10 | 2001-09-20 | Salk Institute For Biological Studies, The | Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US9242014B2 (en) * | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| EP3828205A1 (en) * | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| DK3252076T3 (da) * | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| SG10201600912SA (en) * | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
| EA033110B1 (ru) * | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| EP2906599B1 (en) * | 2012-10-12 | 2019-07-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| JP2017501712A (ja) | 2013-12-18 | 2017-01-19 | イントレキソン コーポレーション | 単鎖ｉｌ−１２核酸、ポリペプチド、およびそれらの使用 |
| KR102048855B1 (ko) * | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| JP2017522893A (ja) * | 2014-07-31 | 2017-08-17 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｒｏｒ１特異的多重鎖キメラ抗原受容体 |
| SG11201702295UA (en) | 2014-09-22 | 2017-04-27 | Intrexon Corp | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| JP6865688B2 (ja) * | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| CN108137669B (zh) * | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| SG11201802912PA (en) | 2015-10-10 | 2018-05-30 | Intrexon Corp | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| US11060088B2 (en) | 2016-02-12 | 2021-07-13 | University Of Massachusetts | Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| SG11201810640RA (en) * | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| AU2017368248A1 (en) * | 2016-11-30 | 2019-06-06 | Intrexon Corporation | Steroid administration and immunotherapy |
| CN110291200B (zh) * | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| KR20190102259A (ko) * | 2017-01-10 | 2019-09-03 | 인트렉손 코포레이션 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
| EP3635132A4 (en) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| EP3697438A4 (en) * | 2017-10-18 | 2021-08-18 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS WITH SPACERS |
| SG11202009697RA (en) | 2018-03-30 | 2020-10-29 | Univ Geneve | Micro rna expression constructs and uses thereof |
| EP3820484A4 (en) | 2018-07-10 | 2022-05-04 | Precigen, Inc. | ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF |
-
2019
- 2019-07-10 EP EP19833113.4A patent/EP3820484A4/en active Pending
- 2019-07-10 JP JP2021500519A patent/JP2021530217A/ja active Pending
- 2019-07-10 SG SG11202100205UA patent/SG11202100205UA/en unknown
- 2019-07-10 WO PCT/US2019/041213 patent/WO2020014366A1/en not_active Ceased
- 2019-07-10 KR KR1020217002650A patent/KR20210043562A/ko not_active Ceased
- 2019-07-10 CA CA3105816A patent/CA3105816A1/en active Pending
- 2019-07-10 CN CN201980059126.7A patent/CN112714769A/zh active Pending
- 2019-07-10 AU AU2019301147A patent/AU2019301147B2/en active Active
-
2021
- 2021-01-07 IL IL280029A patent/IL280029A/en unknown
- 2021-01-07 US US17/143,386 patent/US12275772B2/en active Active
- 2021-01-19 ZA ZA2021/00391A patent/ZA202100391B/en unknown
-
2024
- 2024-02-16 JP JP2024022330A patent/JP2024073449A/ja active Pending
-
2025
- 2025-03-12 US US19/077,365 patent/US20260035432A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530217A5 (https=) | ||
| JPWO2020014366A5 (https=) | ||
| JP2021525534A5 (https=) | ||
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| JP2019517267A5 (https=) | ||
| JP2024138280A5 (https=) | ||
| ES2329334T3 (es) | Formas multimericas de ligandos de la superfamilia de tnf. | |
| KR102044948B1 (ko) | 동종이합체 단백질 구조물 | |
| JP2023085527A5 (https=) | ||
| KR20180043841A (ko) | 키메라 항원 수용체 및 이의 용도 | |
| CN118184790A (zh) | Plap-car-效应细胞 | |
| CN113881694A (zh) | 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体 | |
| KR20220117915A (ko) | 항-muc1 조성물 및 사용 방법 | |
| WO2022029431A1 (en) | Chimeric receptor binding tgf-beta | |
| JP2022521278A (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| CA2921866C (en) | Rna viruses for immunovirotherapy | |
| AU2003228180A1 (en) | Modulators and inhibitors of fibroblast growth factor receptor 5_polypeptides and gene expression thereof | |
| WO2019101062A9 (zh) | 重组疫苗及其应用 | |
| JPWO2019236577A5 (https=) | ||
| US7083791B2 (en) | Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides | |
| JP4635255B2 (ja) | 抗体医薬 | |
| EP4061385A1 (en) | A method for redesign and expansion of nk92 cells for use in immunotherapy | |
| US20050009750A1 (en) | Fibroblast growth factor receptors and methods for their use | |
| WO2022150379A1 (en) | Nk cell engager molecules and methods of use | |
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer |